CRD-4730 not checked
Cardurion Pharmaceuticals, Inc.
FollowEvery change as it happens, and a Monday email
Trials
2 active
3 in total · 3 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Catecholaminergic Polymorphic Ventricular Tachycardia, Heart Failure With Reduced Ejection Fraction (HFrEF)
- Main trialPhase 2
- “This is a Phase 2, multicenter, double-blind, sponsor blinded, placebo-controlled, repeat-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). Participants with CPVT will complete a 3-period, randomized 3-sequence study. Each participant will be randomized to one of the 3 sequences in which they will receive 2 different doses of CRD-4730 and 1 dose of matching placebo.”In the company’s words, NCT06658899 on ClinicalTrials.gov
Other drugs for Catecholaminergic Polymorphic Ventricular Tachycardia
Coming up2
- Apr 2027Phase 2 trial completes · ClinicalTrials.gov
- Sep 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Apr 2027 | A Phase 2 Study of CRD-4730 in CPVT | |
| Phase 2Recruiting | Sep 2028 | A Trial of CRD-4730 in HFrEF | |
| Phase 2Terminated | 31 May 2025 | Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026